StockData

Keysight Technologies vs MKS

KEYS and MKSI side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KEYS and MKSI compare

Keysight Technologies is the larger company, worth 3.5 times as much as MKS ($48.4B against $14.0B).

On earnings, MKS is cheaper: it trades at 33.0× trailing earnings, against 39.0× for Keysight Technologies.

Keysight Technologies grew revenue faster over the last twelve months (25.5% versus 16.3% for MKS).

Keysight Technologies keeps more of each dollar of sales as profit, with a net margin of 19.1% compared with 10.1% at MKS.

MKS pays a dividend yielding 0.47%; Keysight Technologies does not pay one.

MKS scores higher on the StockData Score (15 against 14 for Keysight Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKEYSMKSI
Size and price
Market cap$48.4B$14.0B
Share price$284.45$206.44
Change, 1 year58.9%44.6%
Change, 5 years48.6%33.2%
Beta (5Y)2.002.16
Employees17K10K
StockData Score
Total score1415 (better)
Valuation score12 (better)
Growth score23 (better)
Performance score5 (better)4
Health score6 (better)2
Dividend score04 (better)
Valuation
P/E39.0×33.0× (better)
P/S7.4×3.2× (better)
P/B7.4×4.7× (better)
EV/EBITDA36.3×14.6× (better)
P/FCF33.0×30.7× (better)
FCF yield3.0%3.3% (better)
Fair value$236.11$208.88
Margin of safety−20.5%1.2% (better)
Growth
Revenue growth (TTM)25.5% (better)16.3%
Revenue growth, 5Y average5.0%11.0% (better)
Net income growth (TTM)132% (better)64.8%
EPS growth (TTM)132% (better)58.5%
EPS growth, 5Y average8.2% (better)−7.1%
Profitability
Gross margin64.7% (better)47.0%
Operating margin20.3% (better)15.7%
Net margin19.1% (better)10.1%
FCF margin22.3% (better)10.5%
Return on equity20.6% (better)15.9%
Return on invested capital21.3% (better)20.3%
Financial health
Debt / equity0.38 (better)0.47
Net debt / EBITDA−0.070.92 (better)
Interest coverage12.3× (better)3.7×
Current ratio2.02 (better)1.14
Altman Z-score7.57 (better)2.34
Piotroski F-score66
Dividends and buybacks
Dividend yield–0.47%
Payout ratio–14.3%
Years of dividend growth–0
Dividend growth, 5Y average–1.9%
Buyback yield1.3% (better)0.00%
Shareholder yield1.3% (better)0.47%
Ownership
Held by institutions90.6%105%
Held by insiders0.72%0.48%
Insider net buying, 12 months−$27.7M (better)−$45.6M
Superinvestors holding23 (better)
Short interest, % of float1.3%7.2%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.